Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/11/2008 First Published: 6/1/1999


1.		Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CCCGHS-NCI-T98-0085 NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682


2.		Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				19 to 90				Other				SuMo-Sec-01 PEI 0899/01, IRB 07/03, NCT00108875


3.		Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				LUC 05-003 NCT00365937


4.		Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				20 to 80				Other				FPCR1R2-2 NCT00655785

Last Modified: 10/31/2008 First Published: 11/1/1999


5.		Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-99-C-0158 NCI-T99-0078, T99-0078, NCT00019942

Last Modified: 1/7/2009 First Published: 10/24/2003


6.		Phase II Randomized Study of Multi-Epitope Vaccination With Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E1602 NCT00071981, E1602

Last Modified: 11/16/2008 First Published: 5/28/2004


7.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MCC-15241 MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036


8.		Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				12095B NCT00203892

Last Modified: 11/17/2008 First Published: 3/13/2006


9.		Phase II Randomized Study of Adjuvant gp100 Peptide Immunization With or Without Montanide ISA 51 and/or Imiquimod in Patients With Resected High-Risk Melanoma (Treatment Arms I-IV Closed to Accrual as of 1/11/08)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-06-C-0069 7676, NCI-7676, NCI-P6703, NCT00304057


10.		Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R)]

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2006-0360 NCT00415857

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute